Home » Stocks » Shattuck Labs

Shattuck Labs, Inc. (STTK)

Stock Price: $22.05 USD 1.00 (4.75%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $22.04 -0.01 (-0.05%) Oct 21, 4:03 PM

Stock Price Chart

Key Info

Market Cap 881.16M
Revenue (ttm) 10.76M
Net Income (ttm) -27.41M
Shares Out 39.84M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $22.05
Previous Close $21.05
Change ($) 1.00
Change (%) 4.75%
Day's Open 21.05
Day's Range 21.05 - 22.17
Day's Volume 117,236
52-Week Range 17.51 - 22.90

More Stats

Market Cap 881.16M
Enterprise Value 733.63M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 39.84M
Float 28.43M
EPS (basic) n/a
EPS (diluted) -0.69
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 81.88
PB Ratio 6.71
Revenue 10.76M
Operating Income n/a
Net Income -27.41M
Free Cash Flow n/a
Net Cash 147.53M
Net Cash / Share 3.69
Gross Margin -179.62%
Operating Margin n/a
Profit Margin -254.69%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-55.94%-
Gross Profit9.8922.44
Operating Income-25.07-6.15
Net Income-23.98-7.39
Shares Outstanding7.567.41
Earnings Per Share-3.17-1.00
Operating Cash Flow-20.98-6.90
Capital Expenditures-0.47-1.18
Free Cash Flow-21.45-8.08
Cash & Equivalents39.0960.38
Net Cash / Debt39.0960.38
Book Value-34.55-11.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Shattuck Labs, Inc.
Country United States
Employees 45
CEO Taylor H. Schreiber

Stock Information

Ticker Symbol STTK
Stock Exchange NASDAQ
Sector Health Technology
Industry Biotechnology
Unique Identifier NASDAQ: STTK
IPO Date October 9, 2020


Shattuck Labs, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.